CN104906146A - Medical application of paecilomyces hepidl chen PH40 in resisting depression - Google Patents
Medical application of paecilomyces hepidl chen PH40 in resisting depression Download PDFInfo
- Publication number
- CN104906146A CN104906146A CN201510281896.XA CN201510281896A CN104906146A CN 104906146 A CN104906146 A CN 104906146A CN 201510281896 A CN201510281896 A CN 201510281896A CN 104906146 A CN104906146 A CN 104906146A
- Authority
- CN
- China
- Prior art keywords
- peacilomyce hepiahi
- rat
- mycopowder
- strain
- bacterium strain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a medical application of paecilomyces hepidl chen PH40 in resisting depression, and a remarkable medical effect is achieved. Paecilomyces hepidl chen PH40 bacterial powder is adopted as main components, and multiple kinds of pharmaceutic adjuvant materials are added, thereby preparing tablets, powder, capsules and oral preparations.
Description
Technical field
The invention discloses the medical application of peacilomyce hepiahi bacterium strain PH40 in depression, belong to Chinese medicine and field of health care products.
Background technology
Depression is a kind of common abalienation disease, has become to cause to commit suiside and disabled first cause.Society, life style sharply changes, people's increasing pressure large, very easily causes generation and the development of depression under continuing to be in Chronic Pressure condition.Antidepressant class medicine mostly is steroidal inhibitor, and while the remarkable drug effect of performance, cause the side reaction of serious patient, drug dependence is strong.Past during the decade, eye is placed on the antidepressant activity of natural product by people gradually, and medicinal fungi is because of its high activity, and lower pair acts on the attention day by day causing people in recent years, thus, the research of the macro fungi of carrying out about improving depressed sample symptom receives the extensive concern of field of medicaments researcher.
Summary of the invention
The invention discloses the medical application of a kind of peacilomyce hepiahi bacterium strain PH40 in depression, there is antidepressant activity and obvious medical effect.
Peacilomyce hepiahi bacterium strain PH40 of the present invention with peacilomyce hepiahi bacterium strain (RCEF1429) for original strain, obtain through mutagenesis screening, described bacterial strain is deposited in China typical culture collection center on 26th, preservation address in December in 2014: Wuhan, China Wuhan University; Called after: paecilomyces hepidl chen PH40; Peacilomyce hepiahi bacterium strain PH40; Preserving number is: CCTCC No:M 2014670.
Peacilomyce hepiahi bacterium strain PH40 mycopowder of the present invention is realized by following technical scheme.
Liquid submerged fermentation method fermenting and producing peacilomyce hepiahi bacterium strain PH40, collect fermentation liquid, the centrifugal 10min of 5000r/min, collecting precipitation, lyophilizing, obtains peacilomyce hepiahi bacterium strain PH40 mycelium.
Get peacilomyce hepiahi bacterium strain PH40 mycelium, add pharmaceutic adjuvant, prepare peacilomyce hepiahi bacterium strain PH40 mycopowder preparation.
Adopt Chronic Stress Model to set up depression rat, adopt this depression rat to prove peacilomyce hepiahi bacterium strain antidepressant activity and obvious medical effect.For peacilomyce hepiahi bacterium strain provides foundation as the research and development of antidepressant drug and health product.
Good effect of the present invention is: provide peacilomyce hepiahi mutagenic strain PH40 and prepare purposes in antidepressant drug, have good preventive and therapeutic action to depression.
Detailed description of the invention
In order to technology contents of the present invention can be understood better, describe the present invention below by concrete case study on implementation.
embodiment 1
Get peacilomyce hepiahi bacterium strain PH40 fermentation liquid 1L, the centrifugal 10min of 5000r/min, collecting precipitation, vacuum lyophilization, adopt high speed disintegrator to pulverize, cross 60 mesh sieves, collecting mycopowder, is peacilomyce hepiahi bacterium strain PH40 mycopowder 1
embodiment 2
Get peacilomyce hepiahi bacterium strain PH40 fermentation liquid 1L, spraying dry, collecting mycopowder, is peacilomyce hepiahi bacterium strain PH40 mycopowder 2.
embodiment 3
Get peacilomyce hepiahi bacterium strain PH40 fermentation liquid 1L, the centrifugal 10min of 5000r/min, collecting precipitation, vacuum lyophilization, adopt high speed disintegrator to pulverize, cross 60 mesh sieves, collecting mycopowder, is peacilomyce hepiahi bacterium strain PH40 mycopowder 3; Get mycopowder 3, add the pharmaceutic adjuvant such as sodium bicarbonate, sodium carboxymethyl cellulose, prepare peacilomyce hepiahi bacterium strain PH40 mycopowder preparation 3.
below test shows the purposes of the present invention in antidepressant health product
1, materials and methods
1.1 tested material embodiment 1 mycopowder 1, embodiment 2 mycopowder 2, embodiment 3 preparation 3.
1.2 laboratory animal
Healthy SD male rat 200 is provided, body weight 180-220g by Jilin University's Experimental Animal Center.Be divided into 5 groups at random, often organize 40.
1.3 zoopery room environmentals
Temperature 22 DEG C, humidity 52%.
1.4 dosage choice
The recommended dose of this health-care preparation is adult's (calculating by body weight 60kg) 1.2g, by 12 times of human body recommended amounts, administration is carried out to rat, three groups of tested materials are configured to normal saline the solution that concentration is 0.02g/ml respectively, the administration of modeling rat oral gavage measured indices after 4 weeks, and gastric infusion volume is 2.0ml/kg.Arrange a blank group, replace tested material to carry out administration with normal saline, gavage volume is identical with tested material simultaneously.
1.5 experimental technique
1.5.1 the foundation of rat chronic Stress model
Blank group rat is normally raised, and model group and peacilomyce hepiahi bacterium strain administration group rat adopt Chronic Stress Model modeling 4 weeks, and rat modeling method is:
Laboratory animal accepted stimulation to 14 o'clock, continuous 28d 9 o'clock every days.Stimulate and comprise 7 kinds, often kind of stimulation carries out 4 times at random;
(1) 12h does not ingest, 12h do not take the photograph water---F;
(2) moist bedding and padding---W;
(3) stand upside down suspension 10min---Z;
(4) confuse right and wrong---H;
(5) forced swimming 5min---C in cold water (16 DEG C);
(6) fixing rat, mosquito forceps clamps tail 1min, and position is in root of the tail 1cm place---T;
(7) 50 DEG C of baking oven baking 5min---S.
1.5.2 sucrose water consumption is tested
The sucrose water consumption experiment carrying out rat for second day after experiment terminates.Sucrose water consumption experiment carries out under the condition of dark (having red light).Before experiment starts, rat is adaptive to drink after the sucrose solution 3d of 1% drinking public water supply 1 day.2h before test, the rat that single cage is raised, normally ingests.After darkness, for donor rat answers 1% sucrose solution and tap water, this process need keeps the position of each test group sucrose water balanced.After 1h, measure the liquid amount of drinking.Sucrose water preference degree (SP) is as the reference of rat enjoyment level.The consumption of sucrose water preference degree 1% sucrose water accounts for the percentage ratio of total flow.
Table 1.1 rat sucrose preference degree
Result shows, and compared with model group, peacilomyce hepiahi bacterium strain PH40 mycopowder and preparation significantly can reduce depression rat sucrose preference degree, and result p<0.005, has significant difference.
1.5.3 the rat tail suspension dead time
After rat successive administration 28d, rat visual and audition are all isolated and is suspended in liftoff 50cm eminence, fix experimental rat apart from the glutinous cream bar in tail point 1-2cm place.Dead time of rat in record 5min, when rat passive suspension and almost complete motionless time be considered as motionless, before offical record, 1min is the rat laundering period, not as experimental data.
Result shows, and compared with model group, peacilomyce hepiahi bacterium strain PH40 mycopowder and preparation significantly can reduce depression rat and hang the tail dead time, result p<0.005, have significant difference.
1.5.4 the rat forced swimming dead time
After rat successive administration 28d, rat is placed on respectively a hydrostatic column that can not escape (diameter 25cm, high 70cm) inner, includes the frozen water that 60cm is high, rat is put into its went swimming.The rat continuous dead time in the rear 5min of record 6min, when rat stops struggling, swim on the water surface, only have and maintain its head and be in necessary action on the water surface, be considered as rat motionless.
Result shows, and compared with model group, peacilomyce hepiahi bacterium strain PH40 mycopowder and preparation can significantly reduce the depression rat forced swimming dead time, result p<0.005, have significant difference.
1.5.5 the change of rat plasma monoamine neurotransmitter
After treatment terminates, rat sacrificed by decapitation, be put on ice platform and taken out hypothalamus rapidly, the normal saline of pre-cooling is adopted to rinse, adopt distilled water low-temperature homogenate, the centrifugal 10min of homogenate 8000r/min, collects supernatant, adopts the content of 5-hydroxy tryptamine (5-HT), dopamine (DA), 5-hydroxyindoleacetic acid (5-HIAA), glucocorticoid (GCS) and norepinephrine (NA) in Elisa kit measurement rat cerebral tissue.
Result shows, and compared with model group, peacilomyce hepiahi bacterium strain PH40 mycopowder and preparation can significantly improve depression rat hypothalamus monoamine neurotransmitters, and result p<0.01, has significant difference.
result proves,peacilomyce hepiahi bacterium strain PH40 mycopowder and preparation have significant antidepressant activity.
Claims (3)
1. peacilomyce hepiahi mutagenic strain PH40 is preparing the medical application in antidepressant drug; Described bacterial strain is in December in 2014 preservation " China typical culture collection center " on the 26th, and preserving number is: CCTCC M 2014670.
2. the preparation method of a peacilomyce hepiahi mutagenic strain PH40 mycopowder, its feature is in utilizing the peacilomyce hepiahi mutagenic strain PH40 fermentation liquid 1L described in claim 1, the centrifugal 10min of 5000r/min, collecting precipitation, vacuum lyophilization, employing high speed disintegrator is pulverized, and crosses 60 mesh sieves, collects mycopowder and get final product.
3. the peacilomyce hepiahi mutagenic strain PH40 mycopowder prepared with claims 2 for main component, in addition multiple pharmaceutic adjuvant, the tablet prepared, powder, capsule and oral formulations.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510281896.XA CN104906146B (en) | 2015-05-28 | 2015-05-28 | Medical applications of the peacilomyce hepiahi bacterium strain PH40 in depression |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510281896.XA CN104906146B (en) | 2015-05-28 | 2015-05-28 | Medical applications of the peacilomyce hepiahi bacterium strain PH40 in depression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104906146A true CN104906146A (en) | 2015-09-16 |
| CN104906146B CN104906146B (en) | 2018-06-12 |
Family
ID=54075865
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510281896.XA Active CN104906146B (en) | 2015-05-28 | 2015-05-28 | Medical applications of the peacilomyce hepiahi bacterium strain PH40 in depression |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104906146B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107779405A (en) * | 2017-08-18 | 2018-03-09 | 山东中医药大学 | A kind of coral Paecilomyces varioti strain and its breeding method, application |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1593226A (en) * | 2004-06-30 | 2005-03-16 | 虞泓 | Health food |
-
2015
- 2015-05-28 CN CN201510281896.XA patent/CN104906146B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1593226A (en) * | 2004-06-30 | 2005-03-16 | 虞泓 | Health food |
Non-Patent Citations (2)
| Title |
|---|
| 李春如等: "几种虫草无性型及其相关真菌体外抑制单胺氧化酶活性研究", 《安徽医药》 * |
| 李火金等: "金水宝胶囊治疗男性更年期综合征的疗效观察", 《中国自然医学杂志》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107779405A (en) * | 2017-08-18 | 2018-03-09 | 山东中医药大学 | A kind of coral Paecilomyces varioti strain and its breeding method, application |
| CN107779405B (en) * | 2017-08-18 | 2021-02-09 | 山东中医药大学 | Paecilomyces corallinus strain and cultivation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104906146B (en) | 2018-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9089583B2 (en) | Pharmaceutical composition for strengthening spleen and stomach and preparation method therefor | |
| CN102153668B (en) | Anticancer Armillaria luteovirens polysaccharide and extraction process thereof | |
| CN105167072A (en) | Production method of functional Chinese wolfberry fruit enzyme and product thereof | |
| CN105017438B (en) | A kind of Radix et Rhizoma Gynurae divaricatae polysaccharide and its application in preparing for immunological regulation and anti-tumor drug and functional food | |
| CN109528814A (en) | A kind of probiotics and its preparation method and application of lactobacillus-fermented Radix Astragali | |
| CN100376283C (en) | Chinese medicinal composition for treating tuberculosis and its preparation method | |
| CN103860602A (en) | Application of phellinus igniarius extract in preparation of medicine for treating liver cancer, cervical cancer and breast cancer | |
| CN104388236A (en) | Grape wine as well as preparation method and application thereof | |
| CN106692361A (en) | Fagopyrum tataricum composition, preparation method thereof, preparations and application | |
| CN108210547B (en) | Preparation method of phyllanthus emblica leaf extract, preparation and anti-artemisia application thereof | |
| CN103989724B (en) | Blood sugar lowering heath food and preparation method thereof | |
| CN105213456A (en) | A kind of anti-fatigue medicament and its production and use | |
| CN104940244B (en) | A kind of application of ethanol extract of great Bai bolts bacterium 95% in pharmacy | |
| CN105106816A (en) | Traditional Chinese medicine healthcare preparation with protection effect on chemical liver injury and preparing method thereof | |
| CN104906146A (en) | Medical application of paecilomyces hepidl chen PH40 in resisting depression | |
| CN103610048B (en) | To chemical damage health food having assistant protection function and preparation method thereof | |
| CN105617021A (en) | Medicine or health product taking dendrobium officinale and beautiful millettia root as raw materials | |
| CN107537028B (en) | Formula for simultaneously assisting in reducing blood sugar and blood pressure and preparation method thereof | |
| CN104286844A (en) | Food, health product or medicine composition capable of improving immunity | |
| CN101804083B (en) | Application of pollen pini and extract thereof in treating inflammatory bowel disease and method for preparing extract | |
| CN103830280A (en) | Preparation method of spirulina extract | |
| CN106727701A (en) | A kind of Contained Serum prepared by Sishen wan and its preparation method and application | |
| CN107048408A (en) | Prepare improves cancer patient illness, the fermentation composition of the plant enzyme of raising life quality effect and preparation method with conditioning | |
| CN106728077A (en) | Composition with regulating intestinal canal Bacterial community and the anti-effect that treats constipation and preparation method and application | |
| CN104839689A (en) | Health product for invigorating spleen, nourishing stomach, resisting fatigue and enhancing immunity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |